Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies

  • Estelle® Phase III studies remain on track to report top-line results in Q3 2018 from Europe/Russia and Q1 2019 from US/Canada

Liège, 23 march 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the minimum number of female cycles required by regulators in both of the pivotal Phase III Estelle® studies have now been successfully completed. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP), and is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada.